Abstract The Notch signal regulates both cell viability and apoptosis, and maintains stemness of various cancers including glioblastoma (GBM). Although Notch signal inhibition may be an effective strategy in treating GBM initiating cells (GICs), its applicability to the different subtypes of GBM remains unclear. Here, we analyzed the effectiveness of MRK003, a preclinical c-secretase inhibitor, on GICs. Nine patient-derived GICs were treated by MRK003, and its efficacy on cell viability, apoptosis, sphere forming ability and Akt expression level which might be related to Notch downstream and be greatly important signals in GBM was evaluated. MRK003 suppressed viability and sphere-formation ability, and induced apoptosis in all GICs in varying doses of MRK003. Based on their sensitivities to MRK003, the nine GICs were divided into ''relatively sensitive'' and ''relatively resistant'' GICs. Sensitivity to MRK003 was associated with its inhibitory effect on Akt pathway. Transgenic expression of the myristoylated Akt vector in relatively sensitive GICs partially rescued the effect of MRK003, suggesting that the effect of MRK003 was, at least in part, mediated through inhibition of the Akt pathway. These GICs were differentiated by the expression of CD44 and CD133 with flow cytometric analysis. The relatively sensitive GICs are CD44-high and CD133-low. The IC 50 of MRK003 in a set of GICs exhibited a negative correlation with CD44 and positive correlation with CD133. Collectively, MRK003 is partially mediated by the Akt pathway and has strong therapeutic potential for CD44-high and CD133-low GICs.
Introduction
Glioblastoma (GBM) is the most malignant primary brain tumor in humans. Despite the momentous progress in surgical and neuro-radiological techniques, the median overall survival period of GBM patients is from 14.6 to 16.0 months post diagnosis without major improvement for decades [1] [2] [3] [4] . GBM is characterized by a heterogeneous population of tumor cells, exhibiting high invasive ability and chemo-and radio-resistance [2] . Accumulated evidence has suggested that tumor initiation is caused by a small fraction of tumor cell termed GBM initiating cells (GICs) [5, 6] . The significance of targeting GICs may be important for successful treatment of GBM [7, 8] .
The Notch signals play a variety of roles in cancer initiation and propagation, and are critical for maintenance of stemness [9] . This pathway is mediated by cell-cell contact, thereby initiating the binding of a ligand to a Notch receptor with subsequent activation of the intracellular signaling events. Upon binding of ligand, Notch intracellular domain (NICD) is released by c-secretase, which then translocates to the nucleus, interacts with the specific transcriptional factors, and subsequently activates downstream target genes [9, 10] . The activation of Notch signaling was identified in a variety of cancers, including GBM [10] [11] [12] [13] [14] [15] . Notch displays intense crosstalk with other oncogenic pathways, including phosphoinositide 3-kinase (PI3K)/Akt pathway that is a major pathway in GBM [16] , Janus-activated kinase (JAK)/STAT pathway, Sonic hedgehog pathway and Wnt pathway [10, [17] [18] [19] [20] [21] . Hence, suppression of the Notch signal inhibition may offer an ideal strategy for the treatment of multiple types of cancers.
MRK003 is expected as a novel Notch inhibitor, and is known to be the most effective small molecule inhibitors amongst several other Notch inhibitors [22] . Data obtained with pre-clinical studies for pancreatic carcinoma, breast cancer, and T cell lymphoblastic leukemia demonstrated that MRK003 significantly suppressed cell proliferation and induced apoptosis in vivo [23] [24] [25] [26] [27] . Recent studies including ours have suggested that MRK003 suppresses both proliferation and invasion of GBM cell lines [19] [20] [21] 28] . In addition, MRK003 suppressed tumor growth and tumor initiation capacity in two GBM neurosphere lines [29] . Saito et al. revealed that Notch inhibition demonstrated good response at rate of 43.9 % for proneural subtype of GBM [30] . However, study with patient-derived GICs treated by MRK003 has never been reported.
In this study, we performed a set of in vitro assays including cell viability assay, apoptosis assay and sphere formation assay to analyze the effect of MRK003 on nine patient-derived GICs. Results of these assays demonstrated that MRK003 suppresses GICs viability and sphere formation, and promotes their apoptosis. Nine GICs was classified into relatively sensitive GICs and relatively resistant GICs. Forced expression of the active form of Akt in MRK003-treated relatively sensitive GICs partially rescued the phenotype caused by MRK003, indicating that the mechanism of action is partially mediated through the Akt pathway. Relatively sensitive GICs expressed high-CD44 and low-CD133. In summary, these data indicate that MRK003 may exhibit significant therapeutic potential for GBM harboring GICs with CD44-high and CD133-low expression.
Materials and methods
GBM patient-derived cell culture and transfection GBM cells used in this study were GICs derived from GBM surgical specimens. Diagnosis was based on the World Health Organization classification [3] . Seven GICs (30R, 1123M, Me83, MD13, 528P, 157NS, and 146NS) were established from freshly resected GBM sample of consenting patients in the Department of Neurological Surgery at The Ohio State University [31] [32] [33] [34] . TGS01 and TGS04 GIC were isolated from surgically removed GBM tissues at the University of Tokyo (by TT and YI) [35] . All GBM cells already have been confirmed as tumor-initiating cells since cultured GBM cells have the ability to selfrenewal in vitro and mimic the original tumor after intracranial transplantation into immunocompromised mice [31] [32] [33] [34] . All patient materials and protocols in this study were approved by the ethics committees of Kanazawa University, the Ohio State University and the University of Tokyo. These GBM-derived neurospheres were cultured as described previously [6, 36, 37] .
Vector
Recombinant pcDNA vectors carrying the constitutive, active myristoylated allele of Akt were used for transfection into 30R and 1123M by Nucleofector Kit (Lonza, Basel, Switzerland) by following the company's protocol.
Compounds
The stock solutions of MRK003 (Merck & Co., Inc.; Whitehouse Station, NJ) were dissolved in DMSO at a concentration of 10 mM. The specificity of MRK003 as a c-secretase inhibitor has been confirmed by us and other investigators [22] [23] [24] [25] 27] .
Viability assay
Cell viability assay was performed with Cell counting kit-8 (DOJINDO, Kumamoto, Japan) by following the company's protocol. Briefly, all the GBM spheres were dissociated into single cell suspensions by StemPro Accutase (Gibco/Life Technologies). These dissociated GICs were seeded at a density of 1 9 10 3 cells/100 ll per well into a 96-well Coaster ultra-low attachment plate (Corning, NY) with either MRK003 or DMSO control for 72 h. IC 50 for MRK003 of each was calculated from non-linear curve fit graph using Graph pad prism 5 (Graph Pad Software, Inc., San Diego).
Apoptosis assay
Apoptosis assay was performed using the Annexin V-FITC detection kit as per the manufacturer's protocol (BD Pharmingen, San Diego, CA). GICs were seeded at a density of 1 9 10 5 cells/2 ml/well in a 6-well plate in neurosphere medium with MRK003 or DMSO control. GICs were treated for 72 h. Annexin V-FITC and propidium iodide (PI) double-positive cells and only Annexin V-FITC positive cells were measured by flow cytometry (JSAN; Bay bioscience Inc., Kobe, Japan).
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Tumorsphere-forming assay
Sphere forming assay was performed as described previously [36, 37] . Briefly, the cultured GICs were dissociated with Stempro Accutase. The dissociated in single-cell suspension (5 9 10 2 cells/200 ll) were seeded in 96-well Coaster Ultra-low attachment plate in 1.0 % methylcellulose neurosphere medium with MRK003 or DMSO (control). After incubation for 7 days, tumorsphere was counted and tumorsphere-diameter was measured.
Western blot
GICs were treated with DMSO or MRK003 for 48 h and then lysed in a buffer containing 100 mM Tris (pH 6.7), 4 % SDS, phosphatase inhibitor (Thermo Fisher Scientific Inc., Waltham, MA) and protease inhibitors (complete mini) (Roche Applied Science, Indianapolis, IN). Western blotting was performed as previously [36, 37] . The following antibodies were used; total Akt, phospho-Akt (Ser473) (1:1,000 dilution, Cell Signaling Technology, 
Results

MRK003 decreased cell viability of patient-derived GICs
We initially investigated the chemosensitivity of the nine GICs to MRK003 by using the viability assay (Fig. 1) . MRK003 decreased viability in all species of GICs in a dose dependent fashion compared with DMSO control. Based on the above results we categorized these cells into two types: the former as relatively sensitive GICs and the latter as relatively resistant GICs. Viability of five relatively sensitive GICs (30R, 1123M, MD13, Me83 and TGS01) decreased dramatically with the use of less than 2 lM MRK003 compared to DMSO control. In contrast, viability of four relatively resistant GICs (528P, 157NS, 146NS, and TGS04) was reduced to half by the addition of more than 3 lM MRK003 compared to DMSO control.
MRK003 induced apoptosis in GICs
Subsequently, we assessed whether the reduction of viability by MRK003 was associated with the induction of apoptosis since the Notch signal was related to apoptosis regulation [10, 17] . As expected, MRK003 induced apoptosis in all species of GICs. In case of the sensitive GIC lines, even less than 4 lM MRK003 induced a significant increase in the apoptosis percentage as compared to the DMSO control (Fig. 2a, Supplementary Fig. 1a) . However, in case of the resistant GIC lines, more than 8 lM MRK003 was required to induce an enhanced rate of apoptosis in comparison to the control (Fig. 2b , supplementary Fig. 1b ). This assay demonstrated that even low concentrations of MRK003 were capable of inducing accelerated apoptosis in GICs and reducing their viability. These findings are parallel with the results of cell viability assay, suggesting that suppression of cell viability by MRK003 might be attributable to apoptosis.
MRK003 inhibited sphere formation of GICs
We employed the tumorsphere forming assay to analyze the role of MRK003 in GICs. The basal sphere forming abilities in the 9 GICs were rich in variety. Our results demonstrated that MRK003 significantly reduced both, sphere-number and -diameter in all species of GICs in a dose dependent manner (Fig. 3a, b ). In the sensitive lines, both sphere-number and -diameter were significantly decreased with the use of up to 2 lM MRK003 (P \ 0.01), and further, sphere formation was completely blocked by 3 lM MRK003. In the resistant lines, although sphere numbers and diameters were suppressed by 2, 4 or 6 lM MRK003, dramatic suppression of sphere formation was achieved with the use of more than 8 lM MRK003, compared with DMSO control (P \ 0.01) (Fig. 3b) . These data supported the observations that MRK003 impaired self-renewal in GICs. MRK003 sensitivity of GICs in the viability and apoptosis assays corresponded well with the sensitivity of the sphere forming assay.
Akt activation modestly improved the effect of MRK003
Notch signal is known to be associated with the subsequent activation of the PI3K/Akt pathway which is related to cell proliferation and the most major pathway in GBM [11, 15, 18, 19] . Therefore, phosphorylation level of Akt was assessed in all GICs after treatment with MRK003 for 48 h. Basal level of phospho-Akt in both the sensitive and the resistant lines were approximately same. It was observed that though MRK003 effectively decreased phospho-Akt level in a dose-dependent manner in the sensitive lines, it poorly affect the phosphorylation level of Akt in the resistant lines (Fig. 4a ). The phospho-Akt level in sensitive lines might be caused that MRK003 could be due to the inhibition of total Akt production. Therefore, this data led us to hypothesize that dephosphorylation of Akt by MRK003 can explain the efficacy for the sensitive lines. We further evaluated whether Akt was responsible for the effectiveness by MRK003 in the sensitive lines. To demonstrate that Akt activation rescues cells from the b Fig. 4 Relatively sensitive GICs exhibited strong inhibition of the Akt pathway by MRK003. Response of MRK003 was not completely dependent on Akt. a GICs treated with MRK003 for 48 h were immunoblotted with phospho-Akt (ser473) and total-Akt. Actin was used as a protein loading control. b Relatively sensitive GIC, 30R was transfected with empty-vector (control) or myristoylated-Akt (myrAkt) vector. Western blot analysis of phospho-Akt and total-Akt was shown. The phosphorylation levels of Akt in control-30R and myrAkt-30R were quantified using ImageJ (1.45 s, National Institutes of Health, Bethesda, MD, USA) and shown as a diagram. Actin was used as loading control. The quantified level of Akt phosphorylation in control-30R with DMSO was considered as to be 1.0. c Viability of myrAkt-30R was only significantly increased than control-30R in 2 lM MRK003. d In tumorsphere-forming assay, myrAkt-30R sphere number and sphere-size were significantly increased compared to control-30R with 1 lM MRK003. Both myrAkt-30R and control-30R exhibited negligible sphere formation in 2 lM MRK003. e Apoptosis assay after MRK003 treatment for 72 h was analyzed by flow cytometry of AnnexinV-FITC. In 2 lM MRK003, the AnnexinV-FITC positive percentage of myrAkt-30R was about 60 %, was significantly decreased in comparison to control-30R. All data were representative. Experiments were conducted in at least triplicate. **P \ 0.01 using two-way ANOVA effect of MRK003, myristoylated Akt vector was constitutively anchored at the membrane for maintaining it in an activated form, and was used for the transfection of the representative relatively sensitive GIC, 30R (myrAkt-30R). MyrAkt-30R exhibited higher levels of Akt activation than 30R transfected with empty vector (control-30R) (Fig. 4b) . Expression of phospho-Akt was completely suppressed in control-30R by MRK003 treatment. In contrast, phosphoAkt levels in myrAkt-30R were maintained by MRK003 treatment, although a dose dependent decrease was observed (Fig. 4b) .
In cell viability assay, the decrease of viability in control-30R by treatment with 2 lM MRK003 was reduced in myrAkt-30R (P \ 0.01). However, rescue of viability was not significant in myrAkt-30R when treated with more than 4 lM MRK003 (Fig. 4c) . It suggested that transfection with myr-Akt only partially abrogated the effect of MRK003. In the tumorsphere-forming assay performed with 1 lM MRK003, number and size were significantly increased in cells transfected with myrAkt-30R as compared to cells transfected with the control-30R (P \ 0.01). However, when the concentration of MRK003 was increased to 2 lM, Akt induction hardly rescued tumorsphere formation (Fig. 4d) . In consistence with the above results, Akt induction only partially suppressed apoptosis from 85.0 ± 3.4 % (mean ± SD) to 60.0 ± 4.2 % upon treatment with 2 lM MRK003 (P \ 0.01) (Fig. 4e) . Altogether, the effect of MRK003 in 30R could not be completely recovered with transfection of the cells with myrAkt. We observed similar results in 1123 M, another population of relatively sensitive GIC used in our study (supplementary Fig. 2a-d) . Accordingly, the effect of MRK003 might be only partially dependent upon the inhibition of the Akt pathway.
CD44-high and CD133-low GICs were sensitive to MRK003 treatment CD44 and CD133 were known as cancer stem cell surface markers [5, [38] [39] [40] . We analyzed the expression of CD44 and CD133 in the nine GICs. Our data indicated that sensitive lines presented high CD44 and low CD133 expression level, and that resistant lines exhibited high level expression of CD133 (Fig. 5a, b, supplementary Fig. 3a,  b) . We further investigated whether the expressions of CD44 and CD133 could serve as indicators of MRK003 sensitivity and analyzed the correlation between CD44 and CD133 expression levels and IC 50 of MRK003. IC 50 of GICs for MRK003 correlated negatively with CD44 expression (P = 0.005, r = -0.865), and positively with CD133 expression (P = 0.037, r = 0.712) (Fig. 5c ). These findings indicated that the expression level of CD44 and CD133 may be useful as biomarkers for MRK003 efficacy.
Discussion
The data in the present study have demonstrated that MRK003 suppressed cell viability and sphere formation ability, and induced apoptosis in GICs derived from multiple patients. These results support effectiveness of MRK003 for GICs properties. Interestingly, GICs were divided into relatively sensitive GICs and relatively resistant GICs against MRK003. MRK003 sensitive and resistant GICs were demonstrated to be different by CD44 and CD133 expressed patterns. This study is the first to demonstrate that MRK003 might have strong therapeutic potential for CD44-high and CD133-low expressed GICs.
Although the downstream details of Notch signaling are yet to be deciphered, the Akt pathway which was crucial pathway in GBM had been known to be associated with Notch downstream signal [10, 13, 17, 20] . Our data demonstrated that phosphorylation of Akt in MRK003 relatively sensitive GICs was remarkably decreased by MRK003 treatment. However, transfection with constitutively active Akt vector could not negate the effect of MRK003 completely, thereby suggesting that the effect of MRK003 was only partially dependent on the inhibition of the Akt pathway. Notch signal is a major regulator of survival pathway to play a prominent role in bridging various pathways. Alternate cross-talk pathways for Notch signaling besides PI3K/Akt are TGF-b, MEK/ERK and JAK/STAT3 pathways [41, 42] , which are also associated with cell proliferation in GBM [17, 20, 43] . The nature of Notch cross-talk system was flexible and was depended on each cell background [41] . Therefore, it is possible that MRK003 inhibits not only Notch signaling but also other pathways. Further investigations are warranted in this regard.
CD44 is reported to be related to tumor initiations and a novel therapeutic target [40, 43] . CD133 is a cell surface marker of cancer initiating cells in several cancer types although its validity remains controversial [5, 44] . In our findings, CD44-high and CD133-low expressed GICs are relatively sensitive to MRK003, whereas CD133-high expressed GICs are relatively resistant to MRK003. One explanation for chemoresistance to MRK003 is that CD133-high GICs may have potential drug resistance gene against chemotherapy. For example, CD133-high GICs possess high level of drug resistance gene, BCRP1 [45] . CD44-enriched GICs was regulated by TGF-b pathway which is a key regulator of malignant phenotype [35, 43, 46] . It may be hypothesized that the effect of Notch inhibition is exhibited partially via the TGF-b inhibition [43, 47] . GBM was segregated into four subtypes based on gene expression signature. CD44 was enriched in the mesenchymal subtype of GBM [48] . In our findings, GICs with high CD44 expression demonstrated to be very sensitive to MRK003. Therefore, MRK003 might be effective to mesenchymal subtype of GBM.
We performed sphere forming assay with other c-secretase inhibitor, DAPT and L685,458. DAPT had the strong effect for 30R which was a relatively sensitive line to MRK003 (supplementary Fig. 4) . On the other hand, L685,458 reduced sphere formation not only in 30R but also in TGS01 and TGS04 (data not shown). Generally, c-secretase inhibitors can be classified according to the chemical structures and pharmacological modes of action. MRK003, DAPT and L685,458 are a sulfonamide-containing non-transition state analog, an azepine-containing non-transition state analog and an azepinecontaining transition state analog, respectively [42, 49] . The different experimental results with three c-secretase inhibitors might be caused by different pharmacological modes of action. These inhibitors might modulate different downstream signaling pathways. In fact, these inhibitors affect various intracellular signaling including PI3K/Akt signaling [50] .
A further point of investigation in our study was to confirm the role of Notch pathway inhibition in effecting the MRK003 response, since the possibility of MRK003 acting via off-targets cannot be ruled out. However, accumulated evidence confirmed the strong effect of MRK003 for cancer initiating cells including leukemia [22, 27] , lymphoma [25] , breast [24, 26] , and pancreas [23] in vitro and in vivo. In this study also, MRK003 provided a therapeutic advantage against the chemo resistant population of GICs derived from the nine patients. Regardless of the specificity of MRK003, it promises to be an effective target therapy for GBM.
In conclusion, results of this study suggested that MRK003 might have significant therapeutic potential for CD44-high and CD133-low expressed GICs (supplementary Fig. 5 ). However, additional pre-clinical studies will be required to address whether MRK003 contributes beneficially to GBM treatment. Conflict of interest All authors disclosed no potential conflicts of interest.
